- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Psoriatic arthritis
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 747KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 143KB)
Risankizumab – March 2022
Risankizumab (Psoriatic arthritis): Injection 150 mg in 1 mL pre-filled syringe, Injection 150 mg in 1 mL pre-filled pen; Skyrizi®
Last updated
1 July 2022